FREE REPORT
Report: Pharma R&D in 2026
How leading pharma R&D organizations redesign their operating model to move faster, smarter, and with less risk.
Get your free copy!
Overview
Pharma R&D is under pressure from all sides: rising complexity, fragmented data, new modalities, and growing coordination gaps between discovery, development, and manufacturing. Traditional end-to-end models can’t keep up, causing delays, rework, and late-stage surprises.
In this report, you'll learn:
- Why classic end-to-end R&D models are slowing innovation
- What "atomization" means for discovery, clinical, CMC, and partnering
- How to reduce late-stage risk with better data and decision flow
- 13 practical actions to modernize your Pharma R&D operating model